Register Interest

Telix Pharmaceuticals Limited (ASX: TLX)

Telix is a late-stage radiopharmaceutical company developing a broad portfolio of diagnostic and therapeutic products using Molecularly Targeted Radiation (MTR). Telix’s products address significant unmet medical needs in oncology, immunology and several rare diseases. Telix’s lead product, Illuccix® (TLX591-CDx) for prostate cancer imaging, has been accepted for filing by the U.S. Food and Drug Administration (FDA) and has been granted Priority Review status by the Australian Therapeutic Goods Administration (TGA). None of Telix’s products have currently received a marketing authorisation in any jurisdiction

First Name

Last Name

Company

Email

Phone (including country code)

Country

Intentions Investor Service Provider Industry Participant

Comments